LIGHT CHAIN AMYLOIDOSIS

LIGHT CHAIN AMYLOIDOSIS

Light chain (AL) amyloidosis is caused by a usually small plasma-cell clone that is able to produce the amyloidogenic lights chains. They are able to misfold and aggregate, deposit in tissues in the form of amyloid fibrils and lead to irreversible organ dysfunction and eventually death if treatment...

Full description

Bibliographic Details
Main Authors:	Paolo Milani, Giampaolo Merlini, Giovanni Palladini
Format:	Article
Language:	English
Published:	PAGEPress Publications 2018-03-01
Series:	Mediterranean Journal of Hematology and Infectious Diseases
Online Access:	https://www.mjhid.org/index.php/mjhid/article/view/3292

Similar Items

Predicting survival in light chain amyloidosis
by: Giovanni Palladini, et al.
Published: (2019-07-01)

Novel Therapies in Light Chain Amyloidosis
by: Paolo Milani, et al.
Published: (2018-05-01)

Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis
by: Giovanni Palladini, et al.
Published: (2021-03-01)

Light chain amyloidosis: the heart of the problem
by: Giampaolo Merlini, et al.
Published: (2013-10-01)

Treating advanced cardiac damage in light chain amyloidosis: still an unmet need
by: Giampaolo Merlini, et al.
Published: (2014-09-01)

Current treatment of AL amyloidosis
by: Giovanni Palladini, et al.
Published: (2009-08-01)

The lung in amyloidosis
by: Paolo Milani, et al.
Published: (2017-09-01)

PB2151: CLINICAL FEATURES AND OUTCOMES OF DIFFUSE PULMONARY LIGHT CHAIN AMYLOIDOSIS: A RARE PRESENTATION OF SYSTEMIC AL AMYLOIDOSIS
by: Rajshekhar Chakraborty, et al.
Published: (2023-08-01)

Bortezomib in the treatment of AL amyloidosis: targeted therapy?
by: Roberto Sitia, et al.
Published: (2007-10-01)

DUAL expectations in light chain amyloidosis
by: Stefan Schönland, et al.
Published: (2020-07-01)

Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient
by: Paolo Swuec, et al.
Published: (2019-03-01)

Update on treatment of light chain amyloidosis
by: Shameem Mahmood, et al.
Published: (2014-02-01)

A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis
by: Giovanni Palladini, et al.
Published: (2013-03-01)

Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach
by: Giovanni Palladini, et al.
Published: (2014-04-01)

The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018
by: Giovanni Palladini, et al.
Published: (2023-01-01)

Dissecting the Molecular Features of Systemic Light Chain (AL) Amyloidosis: Contributions from Proteomics
by: Paola Rognoni, et al.
Published: (2021-08-01)

Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts
by: Iman Meziane, et al.
Published: (2017-10-01)

A strategy for synthesis of pathogenic human immunoglobulin free light chains in E. coli.
by: Paola Rognoni, et al.
Published: (2013-01-01)

S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
by: Efstathios Kastritis, et al.
Published: (2023-08-01)

P1714: HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS IN EUROPE
by: A. Jaccard, et al.
Published: (2022-06-01)

AA amyloidosis: basic knowledge, unmet needs and future treatments
by: Laura Obici, et al.
Published: (2012-05-01)

Bone Marrow Microenvironment in Light-Chain Amyloidosis: In Vitro Expansion and Characterization of Mesenchymal Stromal Cells
by: Chiara Valsecchi, et al.
Published: (2021-10-01)

Monitoring Patients with Light Chain (AL) Amyloidosis during and after Therapy: Response Assessment and Identification of Relapse
by: Paolo Milani, et al.
Published: (2022-01-01)

Light-Chain Cardiac Amyloidosis
by: Gonzalo Barge-Caballero, MD, et al.
Published: (2019-10-01)

AL AMYLOIDOSIS: MECHANISMS OF DISEASE AND BIOMARKERS
by: Giovanni Palladini, et al.
Published: (2022-04-01)

Light-Chain Amyloidosis: The Great Impostor
by: Georgia Stefani, et al.
Published: (2023-12-01)

Pseudoxanthoma Elasticum and Light-Chain Amyloidosis
by: M. Carlesimo, et al.
Published: (2012-09-01)

Retinitis pigmentosa associated with systemic light chain amyloidosis (AL amyloidosis)
by: Salem Bouomrani, et al.
Published: (2021-04-01)

Cardiovascular toxicity from therapies for light chain amyloidosis
by: Paolo Morfino, et al.
Published: (2023-07-01)

Localized Lymph Node Light Chain Amyloidosis
by: Binod Dhakal, et al.
Published: (2015-01-01)

Coexistence of Light Chain and Transthyretin Cardiac Amyloidosis
by: Abhishek Gami, MD, et al.
Published: (2024-04-01)

Global epidemiology of amyloid light-chain amyloidosis
by: Nishant Kumar, et al.
Published: (2022-07-01)

Multiorgan involvement by amyloid light chain amyloidosis
by: Guoliang Li, et al.
Published: (2019-04-01)

Light chain amyloidosis presenting as retiform purpura
by: Yssra S. Soliman, MD, et al.
Published: (2021-06-01)

A conformational fingerprint for amyloidogenic light chains
by: Cristina Paissoni, et al.
Published: (2025-03-01)

P914: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
by: E. Kastritis, et al.
Published: (2022-06-01)

Predictors of Early Death in Patients With Wild‐Type Transthyretin Cardiac Amyloidosis
by: Paolo Milani, et al.
Published: (2025-01-01)

P915: EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
by: E. Kastritis, et al.
Published: (2022-06-01)

Apolipoprotein C-II Deposition Amyloidosis: A Potential Misdiagnosis as Light Chain Amyloidosis
by: Sadichhya Lohani, et al.
Published: (2016-01-01)

Treatment patterns and outcomes in light chain amyloidosis: An institutional registry of amyloidosis report in Argentina.
by: Maria Lourdes Posadas-Martinez, et al.
Published: (2022-01-01)